It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EBS’s FA Score shows that 0 FA rating(s) are green whileELAN’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EBS’s TA Score shows that 6 TA indicator(s) are bullish while ELAN’s TA Score has 5 bullish TA indicator(s).
EBS (@Pharmaceuticals: Generic) experienced а +46.07% price change this week, while ELAN (@Pharmaceuticals: Generic) price change was +22.75% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +5.29%. For the same industry, the average monthly price growth was +12.07%, and the average quarterly price growth was +82.46%.
EBS is expected to report earnings on Nov 05, 2025.
ELAN is expected to report earnings on Nov 11, 2025.
A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
EBS | ELAN | EBS / ELAN | |
Capitalization | 435M | 8.66B | 5% |
EBITDA | 105M | 1.4B | 7% |
Gain YTD | -6.799 | 43.931 | -15% |
P/E Ratio | 3.40 | 19.81 | 17% |
Revenue | 930M | 4.43B | 21% |
Total Cash | 149M | 487M | 31% |
Total Debt | 666M | 4.4B | 15% |
EBS | ELAN | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 75 | 11 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 54 Fair valued | 93 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 96 | 82 | |
PRICE GROWTH RATING 1..100 | 44 | 39 | |
P/E GROWTH RATING 1..100 | 47 | 93 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
EBS's Valuation (54) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew somewhat faster than ELAN’s over the last 12 months.
EBS's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew similarly to ELAN’s over the last 12 months.
ELAN's SMR Rating (82) in the Agricultural Commodities Or Milling industry is in the same range as EBS (96) in the Biotechnology industry. This means that ELAN’s stock grew similarly to EBS’s over the last 12 months.
ELAN's Price Growth Rating (39) in the Agricultural Commodities Or Milling industry is in the same range as EBS (44) in the Biotechnology industry. This means that ELAN’s stock grew similarly to EBS’s over the last 12 months.
EBS's P/E Growth Rating (47) in the Biotechnology industry is somewhat better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that EBS’s stock grew somewhat faster than ELAN’s over the last 12 months.
EBS | ELAN | |
---|---|---|
RSI ODDS (%) | 1 day ago90% | 1 day ago73% |
Stochastic ODDS (%) | 1 day ago86% | 1 day ago75% |
Momentum ODDS (%) | 1 day ago72% | 1 day ago58% |
MACD ODDS (%) | 1 day ago73% | 1 day ago65% |
TrendWeek ODDS (%) | 1 day ago77% | 1 day ago66% |
TrendMonth ODDS (%) | 1 day ago79% | 1 day ago65% |
Advances ODDS (%) | 5 days ago76% | 1 day ago62% |
Declines ODDS (%) | 12 days ago88% | 13 days ago73% |
BollingerBands ODDS (%) | 1 day ago83% | 1 day ago63% |
Aroon ODDS (%) | 1 day ago77% | 1 day ago76% |
A.I.dvisor indicates that over the last year, EBS has been loosely correlated with HROW. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if EBS jumps, then HROW could also see price increases.
Ticker / NAME | Correlation To EBS | 1D Price Change % | ||
---|---|---|---|---|
EBS | 100% | +9.19% | ||
HROW - EBS | 38% Loosely correlated | +3.23% | ||
VTRS - EBS | 37% Loosely correlated | +2.64% | ||
AMRX - EBS | 36% Loosely correlated | +2.04% | ||
SIGA - EBS | 34% Loosely correlated | -1.90% | ||
ELAN - EBS | 32% Poorly correlated | +1.93% | ||
More |
A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.
Ticker / NAME | Correlation To ELAN | 1D Price Change % | ||
---|---|---|---|---|
ELAN | 100% | +1.93% | ||
VTRS - ELAN | 47% Loosely correlated | +2.64% | ||
ZTS - ELAN | 47% Loosely correlated | +0.50% | ||
PAHC - ELAN | 40% Loosely correlated | +3.96% | ||
SNDL - ELAN | 39% Loosely correlated | +0.50% | ||
TLRY - ELAN | 36% Loosely correlated | +3.32% | ||
More |